Improdia is an innovative, diagnostic company that is developing a simple blood test, that monitors the chronic inflammation level of patients suffering from autoimmune and cancer diseases, reflecting the Immune status of patients.
Our novel blood-based test supports the diagnosis and management of chronic immune-mediated diseases.
Through monitoring the immune status of cancer patients, Improdia’s test predicts efficiency of immunotherapy.
Improdia’s test outcome will enable physicians to identify possible development of complications for diabetic patients and predict fatal complications such as heart attack.
Improdia’s technology is based on a wide research performed under supervision of Prof. Michal Baniyash, from Immunology department at the Hebrew University of Jerusalem.
Improdia in vitro diagnostic products measure several biomarkers by a simple, rapid, reliable and non-invasive blood test.
Improdia’s creative technology has enormous potential uses; as a Prognostic/Diagnostic test, which can help pharma companies in their drug development process or to suggest a personalized treatment to patients and to predict patient complications before they are evident.